Dr Price graduated from The University of Sheffield in 2009. Upon completion of specialty training in Nottingham in 2018, he moved to The Christie in Manchester to take up a fellowship in proton beam therapy. He was appointed to a PhD research fellowship studying or opharyngeal cancers (cancers of the tonsil, tongue or throat) in January 2020 and as a Consultant Clinical Oncologist in May 2020. He specialises in the treatment of head and neck cancers with advanced radiotherapy (including IMRT, VMAT and IGRT techniques) and p roton beam therapy (IMPT). Dr Price has an interest in research and acts as radiotherapy quality assurance lead for the UK phase 3 TORPEdO (IMPT vs IMRT for toxicity reduction in oropharyngeal cancer) an d PROTIS (IMPT vs IMRT for the treatment of sinonasal cancer) trials. Other research interests include refining patient selection for (chemo) radiotherapy using mathematical models, and the use of advanced imaging techniques to predict treatment outcomes. Dr Price is the clinical lead for the roll-out of electronic patient-reported outcomes (ePROMs) across clinical teams at The Christie and medical lead for alcohol / smoking services for the Trust. He is a Clinical and Educational supervisor for Clinical Oncology trainees and an examiner for the Royal College of Radiologists.